Faruqi & Faruqi, LLP Announces Investigation of Anadys Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anadys Pharmaceuticals, Inc. (“Anadys” or the “Company”) (NASDAQ: ANDS) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Roche Holding AG (VTX: ROG.VX) in an all-cash deal valued at about $230 million. Under the terms of the proposed transaction, Anadys stockholders will receive $3.70 in cash for each share of Anadys common stock they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $4.00 for Anadys. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.

Back to news